Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0400-0.0900 (-7.96%)
At close: 04:00PM EDT
1.0400 0.00 (0.00%)
After hours: 07:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close1.1300
Open1.1000
Bid1.0200 x 2900
Ask1.0300 x 1000
Day's Range0.9200 - 1.1000
52 Week Range0.4600 - 6.9800
Volume989,043
Avg. Volume3,815,601
Market Cap11.488M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5300
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HTGM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HTG Molecular Diagnostics, Inc.
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    HTG Molecular Diagnostics Reports Second Quarter 2022 Results

    Call scheduled for today, August 11, 2022, at 4:30 pm ETTUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a

  • Zacks

    Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

    Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

    TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Easte

Advertisement
Advertisement